[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f20F-RJDtcp9060bIsyoPO0qbWKdFJX5ozz02h80UoGs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":8,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":35,"rows":42},"Regional Hospital Holstebro",[4],52,false,0,1,2530,22,[13,16,19,22,24,27,29,32],{"name":14,"count":15},"Healthy",12,{"name":17,"count":18},"Nephropathy",6,{"name":20,"count":21},"Essential Hypertension",4,{"name":23,"count":21},"Obstructive Sleep Apnea",{"name":25,"count":26},"Hypertension",3,{"name":28,"count":26},"Renal Failure, Chronic",{"name":30,"count":31},"Cardiovascular Diseases",2,{"name":33,"count":31},"Chronic Kidney Diseases",[],[36,37,38,39,40,41],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[43,87,134,164,196,218,242,265,283,307,333,351,372,395,436,471,497,515,533,595,627],{"intervention":44,"totalTrials":26,"cells":45},"Atorvastatin",{"EARLY_PHASE1":46,"PHASE1":48,"PHASE2":50,"PHASE3":62,"PHASE4":64,"NA":85},{"trials":47,"activeCount":8},[],{"trials":49,"activeCount":8},[],{"trials":51,"activeCount":8},[52],{"nctId":53,"briefTitle":54,"status":55,"phases":56,"primaryCompletion":57,"completion":57,"start":58,"enrollment":59,"conditions":60,"interventions":61},"NCT01214746","The Effects of Atorvastatin on the Nitric Oxide-system in Healthy Young Man","COMPLETED",[38],"2011-06","2010-05",26,[30,17],[44],{"trials":63,"activeCount":8},[],{"trials":65,"activeCount":8},[66,76],{"nctId":67,"briefTitle":68,"status":55,"phases":69,"primaryCompletion":70,"completion":70,"start":71,"enrollment":72,"conditions":73,"interventions":75},"NCT00678184","The Effect of Atorvastatin on Renal Function in Healthy Subjects During Normal and High Sodium Intake",[40],"2007-10","2007-01",23,[74],"Healthy Subjects",[44],{"nctId":77,"briefTitle":78,"status":55,"phases":79,"primaryCompletion":80,"completion":80,"start":81,"enrollment":82,"conditions":83,"interventions":84},"NCT00678522","The Acute Effect of Atorvastain on Renal Function in Patients With Type II Diabetes",[40],"2008-05","2007-09",25,[74],[44],{"trials":86,"activeCount":8},[],{"intervention":88,"totalTrials":26,"cells":89},"Voluven",{"EARLY_PHASE1":90,"PHASE1":92,"PHASE2":94,"PHASE3":96,"PHASE4":98,"NA":132},{"trials":91,"activeCount":8},[],{"trials":93,"activeCount":8},[],{"trials":95,"activeCount":8},[],{"trials":97,"activeCount":8},[],{"trials":99,"activeCount":8},[100,112,123],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":110},"NCT01486550","Hydroxyethyl Starch and Renal Function After Laparoscopic Nephrectomy","TERMINATED",[40],"2014-09","2011-12",14,[109],"Kidney Cancer",[88,111],"Sodium Chloride 9mg\u002Fml",{"nctId":113,"briefTitle":114,"status":55,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":121},"NCT01486576","Hydroxyethyl Starch and Renal Function After Hip Replacement Surgery",[40],"2013-03","2012-01",42,[120],"Osteoarthritis",[88,122],"Sodium Chloride 9 mg\u002Fml",{"nctId":124,"briefTitle":125,"status":55,"phases":126,"primaryCompletion":127,"completion":127,"start":117,"enrollment":128,"conditions":129,"interventions":131},"NCT01486563","Hydroxyethyl Starch and Renal Function After Radical Prostatectomy",[40],"2013-06",40,[130],"Prostate Cancer",[88,122],{"trials":133,"activeCount":8},[],{"intervention":135,"totalTrials":31,"cells":136},"Eprosartan",{"EARLY_PHASE1":137,"PHASE1":139,"PHASE2":141,"PHASE3":143,"PHASE4":145,"NA":162},{"trials":138,"activeCount":8},[],{"trials":140,"activeCount":8},[],{"trials":142,"activeCount":8},[],{"trials":144,"activeCount":8},[],{"trials":146,"activeCount":8},[147,155],{"nctId":148,"briefTitle":149,"status":55,"phases":150,"completion":151,"start":71,"enrollment":152,"conditions":153,"interventions":154},"NCT00438945","The Effect of Eprosartan on Hormones and Kidney Function in Patients With Essential Hypertension",[40],"2008-01",18,[20],[135],{"nctId":156,"briefTitle":157,"status":55,"phases":158,"start":159,"enrollment":152,"conditions":160,"interventions":161},"NCT00409903","The Effect of Eprosartan on Hormones and Kidney Function in Healthy Humans.",[40],"2006-11",[14],[135],{"trials":163,"activeCount":8},[],{"intervention":165,"totalTrials":31,"cells":166},"HMG-CoA reductase inhibition",{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":194},{"trials":168,"activeCount":8},[],{"trials":170,"activeCount":8},[],{"trials":172,"activeCount":8},[],{"trials":174,"activeCount":8},[],{"trials":176,"activeCount":8},[177,186],{"nctId":178,"briefTitle":179,"status":55,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":185},"NCT00344955","Acute Effect of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects",[40],"2003-12","2003-01",20,[14],[165],{"nctId":187,"briefTitle":188,"status":55,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":183,"conditions":192,"interventions":193},"NCT00345202","Short Term Effects of HMG-CoA Reductase Inhibition (Atorvastatin)on Renal Hemodynamics, Tubular Function and Vasoactive Hormones on Healthy Subjects",[40],"2005-02","2004-09",[14],[165],{"trials":195,"activeCount":8},[],{"intervention":122,"totalTrials":31,"cells":197},{"EARLY_PHASE1":198,"PHASE1":200,"PHASE2":202,"PHASE3":204,"PHASE4":206,"NA":216},{"trials":199,"activeCount":8},[],{"trials":201,"activeCount":8},[],{"trials":203,"activeCount":8},[],{"trials":205,"activeCount":8},[],{"trials":207,"activeCount":8},[208,212],{"nctId":113,"briefTitle":114,"status":55,"phases":209,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":210,"interventions":211},[40],[120],[88,122],{"nctId":124,"briefTitle":125,"status":55,"phases":213,"primaryCompletion":127,"completion":127,"start":117,"enrollment":128,"conditions":214,"interventions":215},[40],[130],[88,122],{"trials":217,"activeCount":8},[],{"intervention":219,"totalTrials":9,"cells":220},"dialysisis with and without glucose in the dialysis",{"EARLY_PHASE1":221,"PHASE1":223,"PHASE2":225,"PHASE3":227,"PHASE4":229,"NA":240},{"trials":222,"activeCount":8},[],{"trials":224,"activeCount":8},[],{"trials":226,"activeCount":8},[],{"trials":228,"activeCount":8},[],{"trials":230,"activeCount":8},[231],{"nctId":232,"briefTitle":233,"status":55,"phases":234,"completion":235,"start":235,"enrollment":236,"conditions":237,"interventions":239},"NCT00278057","STUDY OF GLUCOSE IN DIALYSIS WATER WITH REGARD TO BLOOD PRESSURE AND QUALITY OF LIFE",[40],"2003-05",55,[238],"Hemodialysis",[219],{"trials":241,"activeCount":8},[],{"intervention":243,"totalTrials":9,"cells":244},"Methylprednisolone",{"EARLY_PHASE1":245,"PHASE1":247,"PHASE2":249,"PHASE3":251,"PHASE4":253,"NA":263},{"trials":246,"activeCount":8},[],{"trials":248,"activeCount":8},[],{"trials":250,"activeCount":8},[],{"trials":252,"activeCount":8},[],{"trials":254,"activeCount":8},[255],{"nctId":256,"briefTitle":257,"status":55,"phases":258,"primaryCompletion":259,"completion":259,"start":260,"enrollment":183,"conditions":261,"interventions":262},"NCT00281710","Urinary Aquaporin 2 Excretion After Methylprednisolone in Fasting Healthy Humans",[40],"2007-02","2005-10",[14],[243],{"trials":264,"activeCount":8},[],{"intervention":111,"totalTrials":9,"cells":266},{"EARLY_PHASE1":267,"PHASE1":269,"PHASE2":271,"PHASE3":273,"PHASE4":275,"NA":281},{"trials":268,"activeCount":8},[],{"trials":270,"activeCount":8},[],{"trials":272,"activeCount":8},[],{"trials":274,"activeCount":8},[],{"trials":276,"activeCount":8},[277],{"nctId":101,"briefTitle":102,"status":103,"phases":278,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":279,"interventions":280},[40],[109],[88,111],{"trials":282,"activeCount":8},[],{"intervention":284,"totalTrials":9,"cells":285},"Dihydralazine",{"EARLY_PHASE1":286,"PHASE1":288,"PHASE2":290,"PHASE3":292,"PHASE4":294,"NA":305},{"trials":287,"activeCount":8},[],{"trials":289,"activeCount":8},[],{"trials":291,"activeCount":8},[],{"trials":293,"activeCount":8},[],{"trials":295,"activeCount":8},[296],{"nctId":297,"briefTitle":298,"status":55,"phases":299,"primaryCompletion":300,"completion":300,"start":301,"enrollment":302,"conditions":303,"interventions":304},"NCT00311974","The Effect of Dihydralazine on Kidney Function and Hormones in Healthy Individuals",[40],"2007-11","2006-04",16,[14],[284],{"trials":306,"activeCount":8},[],{"intervention":308,"totalTrials":9,"cells":309},"Plasma-lyte",{"EARLY_PHASE1":310,"PHASE1":312,"PHASE2":314,"PHASE3":316,"PHASE4":318,"NA":331},{"trials":311,"activeCount":8},[],{"trials":313,"activeCount":8},[],{"trials":315,"activeCount":8},[],{"trials":317,"activeCount":8},[],{"trials":319,"activeCount":8},[320],{"nctId":321,"briefTitle":322,"status":323,"phases":324,"primaryCompletion":325,"completion":325,"start":326,"enrollment":128,"conditions":327,"interventions":329},"NCT02528448","0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis","UNKNOWN",[40],"2016-02","2015-03",[328],"Nephrotoxicity",[308,330],"0,9% saline",{"trials":332,"activeCount":8},[],{"intervention":330,"totalTrials":9,"cells":334},{"EARLY_PHASE1":335,"PHASE1":337,"PHASE2":339,"PHASE3":341,"PHASE4":343,"NA":349},{"trials":336,"activeCount":8},[],{"trials":338,"activeCount":8},[],{"trials":340,"activeCount":8},[],{"trials":342,"activeCount":8},[],{"trials":344,"activeCount":8},[345],{"nctId":321,"briefTitle":322,"status":323,"phases":346,"primaryCompletion":325,"completion":325,"start":326,"enrollment":128,"conditions":347,"interventions":348},[40],[328],[308,330],{"trials":350,"activeCount":8},[],{"intervention":352,"totalTrials":9,"cells":353},"NSAID",{"EARLY_PHASE1":354,"PHASE1":356,"PHASE2":358,"PHASE3":360,"PHASE4":362,"NA":370},{"trials":355,"activeCount":8},[],{"trials":357,"activeCount":8},[],{"trials":359,"activeCount":8},[],{"trials":361,"activeCount":8},[],{"trials":363,"activeCount":8},[364],{"nctId":365,"briefTitle":366,"status":55,"phases":367,"primaryCompletion":71,"completion":71,"enrollment":183,"conditions":368,"interventions":369},"NCT00281762","Urinary Aquaporin 2 Excretion After NSAID in Fasting Healthy Human",[40],[14],[352],{"trials":371,"activeCount":8},[],{"intervention":373,"totalTrials":9,"cells":374},"L-NMMA",{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":383,"NA":393},{"trials":376,"activeCount":8},[],{"trials":378,"activeCount":8},[],{"trials":380,"activeCount":8},[],{"trials":382,"activeCount":8},[],{"trials":384,"activeCount":8},[385],{"nctId":386,"briefTitle":387,"status":55,"phases":388,"completion":389,"start":390,"enrollment":128,"conditions":391,"interventions":392},"NCT00410085","Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls",[40],"2005-11","2005-01",[23,14],[373],{"trials":394,"activeCount":8},[],{"intervention":396,"totalTrials":26,"cells":397},"Tolvaptan",{"EARLY_PHASE1":398,"PHASE1":400,"PHASE2":402,"PHASE3":421,"PHASE4":432,"NA":434},{"trials":399,"activeCount":8},[],{"trials":401,"activeCount":8},[],{"trials":403,"activeCount":8},[404,412],{"nctId":405,"briefTitle":406,"status":55,"phases":407,"primaryCompletion":408,"completion":408,"start":409,"enrollment":183,"conditions":410,"interventions":411},"NCT01638663","Effect of the Aquaretic Tolvaptan on Nitric Oxide System (TORA)",[38],"2014-03","2012-05",[30,17],[396],{"nctId":413,"briefTitle":414,"status":55,"phases":415,"primaryCompletion":416,"completion":416,"start":417,"enrollment":152,"conditions":418,"interventions":420},"NCT02527863","Effect of the Aquaretic Tolvaptan on Nitric Oxide System",[38],"2016-08","2015-02",[419],"Autosomal Dominant Polycystic Kidney Disease",[396],{"trials":422,"activeCount":8},[423],{"nctId":424,"briefTitle":425,"status":55,"phases":426,"primaryCompletion":427,"completion":427,"start":428,"enrollment":183,"conditions":429,"interventions":431},"NCT03803124","Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD",[39],"2017-12-15","2015-12",[430],"Polycystic Kidney, Autosomal Dominant",[396],{"trials":433,"activeCount":8},[],{"trials":435,"activeCount":8},[],{"intervention":437,"totalTrials":31,"cells":438},"Cholecalciferol",{"EARLY_PHASE1":439,"PHASE1":441,"PHASE2":443,"PHASE3":465,"PHASE4":467,"NA":469},{"trials":440,"activeCount":8},[],{"trials":442,"activeCount":8},[],{"trials":444,"activeCount":8},[445,455],{"nctId":446,"briefTitle":447,"status":55,"phases":448,"primaryCompletion":449,"completion":449,"start":450,"enrollment":451,"conditions":452,"interventions":454},"NCT01312714","Vitamin D3 Supplementation in Dialysis Patients",[38],"2012-09","2011-02",64,[453],"End-Stage Renal Disease",[437],{"nctId":456,"briefTitle":457,"status":55,"phases":458,"primaryCompletion":459,"completion":459,"start":460,"enrollment":461,"conditions":462,"interventions":464},"NCT01166165","Effect of Vitamin D Replacement During Winter Months in Patients With Hypertension",[38],"2011-04","2010-07",136,[25,463],"Vitamin D Deficiency",[437],{"trials":466,"activeCount":8},[],{"trials":468,"activeCount":8},[],{"trials":470,"activeCount":8},[],{"intervention":472,"totalTrials":9,"cells":473},"15 mg tolvaptan",{"EARLY_PHASE1":474,"PHASE1":476,"PHASE2":478,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":475,"activeCount":8},[],{"trials":477,"activeCount":8},[],{"trials":479,"activeCount":8},[480],{"nctId":481,"briefTitle":482,"status":55,"phases":483,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":487,"interventions":488},"NCT02078973","Effect of the Aquaretic Tolvaptan on Nitric Oxide System. A Dose-response Study (DOVA)",[38],"2016-01","2014-03-01",15,[17],[472,489,490],"30 mg tolvaptan","45 mg tolvaptan",{"trials":492,"activeCount":8},[],{"trials":494,"activeCount":8},[],{"trials":496,"activeCount":8},[],{"intervention":489,"totalTrials":9,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":500,"activeCount":8},[],{"trials":502,"activeCount":8},[],{"trials":504,"activeCount":8},[505],{"nctId":481,"briefTitle":482,"status":55,"phases":506,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":507,"interventions":508},[38],[17],[472,489,490],{"trials":510,"activeCount":8},[],{"trials":512,"activeCount":8},[],{"trials":514,"activeCount":8},[],{"intervention":490,"totalTrials":9,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":518,"activeCount":8},[],{"trials":520,"activeCount":8},[],{"trials":522,"activeCount":8},[523],{"nctId":481,"briefTitle":482,"status":55,"phases":524,"primaryCompletion":484,"completion":484,"start":485,"enrollment":486,"conditions":525,"interventions":526},[38],[17],[472,489,490],{"trials":528,"activeCount":8},[],{"trials":530,"activeCount":8},[],{"trials":532,"activeCount":8},[],{"intervention":534,"totalTrials":18,"cells":535},"Ng-monomethyl-L-arginine",{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":579,"PHASE3":581,"PHASE4":583,"NA":585},{"trials":537,"activeCount":8},[],{"trials":539,"activeCount":8},[540,548,554,563,572],{"nctId":541,"briefTitle":542,"status":55,"phases":543,"enrollment":544,"conditions":545,"interventions":547},"NCT00344734","Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure",[37],30,[546],"Congestive Heart Failure",[534],{"nctId":549,"briefTitle":550,"status":55,"phases":551,"enrollment":544,"conditions":552,"interventions":553},"NCT00345150","Effects of Inhibition of NO-Synthesis on Renal Hemodynamics and Sodium Excretion in Patients With Essential Hypertension and Healthy Controls",[37],[25],[534],{"nctId":555,"briefTitle":556,"status":55,"phases":557,"primaryCompletion":558,"completion":558,"start":559,"enrollment":15,"conditions":560,"interventions":561},"NCT01070940","L-NMMA Dose-response Study in Healthy Subjects",[37],"2010-06","2010-02",[14],[562,562,562],"NG-monomethyl-L-arginine",{"nctId":564,"briefTitle":565,"status":55,"phases":566,"enrollment":567,"conditions":568,"interventions":571},"NCT00345137","Effects of Systemic NO-Inhibition on Renal Hemodynamics in Patiens With Polycystic Kidney Disease and Chronic Glomerulonephritis",[37],75,[569,570],"ADPKD","Glomerulonephritis",[534],{"nctId":573,"briefTitle":574,"status":55,"phases":575,"enrollment":544,"conditions":576,"interventions":578},"NCT00344916","Phase 1 Study of L-NMMA in Patients With Liver Cirrhosis",[37],[577],"Liver Cirrhosis",[534],{"trials":580,"activeCount":8},[],{"trials":582,"activeCount":8},[],{"trials":584,"activeCount":8},[],{"trials":586,"activeCount":8},[587],{"nctId":588,"briefTitle":589,"status":323,"phases":590,"primaryCompletion":408,"completion":591,"start":592,"enrollment":544,"conditions":593,"interventions":594},"NCT01617551","Effect of Renal Denervation on NO-mediated Sodium Excretion and Plasma Levels of Vasoactive Hormones",[41],"2014-06","2012-03",[20],[562],{"intervention":596,"totalTrials":31,"cells":597},"Amiloride",{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":617},{"trials":599,"activeCount":8},[],{"trials":601,"activeCount":8},[602],{"nctId":603,"briefTitle":604,"status":55,"phases":605,"primaryCompletion":460,"completion":460,"start":606,"enrollment":544,"conditions":607,"interventions":609},"NCT00857909","The Effect of Amiloride and Spironolactone in Healthy Persons",[37],"2009-01",[608],"High Blood Pressure",[596,610,610],"Spironolactone",{"trials":612,"activeCount":8},[],{"trials":614,"activeCount":8},[],{"trials":616,"activeCount":8},[],{"trials":618,"activeCount":8},[619],{"nctId":620,"briefTitle":621,"status":55,"phases":622,"primaryCompletion":623,"completion":623,"start":624,"enrollment":82,"conditions":625,"interventions":626},"NCT01195805","The Effects of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables",[41],"2015-08","2010-08",[20],[610,596],{"intervention":610,"totalTrials":31,"cells":628},{"EARLY_PHASE1":629,"PHASE1":631,"PHASE2":637,"PHASE3":639,"PHASE4":641,"NA":643},{"trials":630,"activeCount":8},[],{"trials":632,"activeCount":8},[633],{"nctId":603,"briefTitle":604,"status":55,"phases":634,"primaryCompletion":460,"completion":460,"start":606,"enrollment":544,"conditions":635,"interventions":636},[37],[608],[596,610,610],{"trials":638,"activeCount":8},[],{"trials":640,"activeCount":8},[],{"trials":642,"activeCount":8},[],{"trials":644,"activeCount":8},[645],{"nctId":620,"briefTitle":621,"status":55,"phases":646,"primaryCompletion":623,"completion":623,"start":624,"enrollment":82,"conditions":647,"interventions":648},[41],[20],[610,596]]